Androgen deficiency in men

Endocrinologist

Volumn 17, Issue 2, 2007, Pages 101-115

  Tung, Daniel S ^a,b   Cunningham, Glenn R ^a,c,d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

^c St Luke's Baylor Diabetes Program   (United States)

^d NONE   (United States)

Author keywords

Androgen deficiency; Hypogonadism; Testosterone; Testosterone deficiency; Testosterone treatment

Indexed keywords

ANABOLIC AGENT; ANDROGEN; CANNABINOID; FINASTERIDE; FLUOXYMESTERONE; GONADORELIN DERIVATIVE; KETOCONAZOLE; LUTEINIZING HORMONE; METHYLTESTOSTERONE; NANDROLONE DECANOATE; OPIATE; PLACEBO; RECOMBINANT CHORIONIC GONADOTROPIN; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; STEROID; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TESTOSTERONE ENANTATE;

ACNE; AGE DISTRIBUTION; ALOPECIA; ANDROGEN BLOOD LEVEL; ANDROGEN DEFICIENCY; APPLICATION SITE REACTION; BODY COMPOSITION; BONE DENSITY; CARDIOVASCULAR RISK; CHRONIC LIVER DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; ERYTHROCYTOSIS; FLUID RETENTION; FLUSHING; GYNECOMASTIA; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOGONADISM; HYPOPHYSIS DISEASE; HYPOTHALAMUS; HYPOTHALAMUS DISEASE; HYPOTHYROIDISM; KIDNEY DISEASE; LIBIDO DISORDER; LIVER CELL DAMAGE; LIVER DISEASE; LIVER INJURY; LOWER URINARY TRACT SYMPTOM; LUMBAR SPINE; LUTEINIZING HORMONE BLOOD LEVEL; MALE INFERTILITY; MOOD CHANGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OILY SKIN; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SEXUAL FUNCTION; SIDE EFFECT; SKIN MANIFESTATION; SLEEP APNEA SYNDROME; TABLET; TESTIS DISEASE; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL;

EID: 34247137940     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000260860.68375.96     Document Type: Review

References (96)

1. Morley JE, Kaiser FE, Perry HM 3rd, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997;46:410-413.
2. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-731.
3. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920-5926.
4. The Endocrine Society. The Endocrine Society 2001 Summary from the 2nd Annual Andropause Consensus Meeting. Chevy Chase, MD: The Endocrine Society.
5. Sodergard R, Backstrom T, Shanbhag V, et al. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982;16:801-810.
6. Vermeulen A, Verdonck L, Kaufman J. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672.
7. Luke MC, Coffey DS. Human androgen receptor binding to the androgen response element of prostate specific antigen. J Androl. 1994;15: 41-51.
8. Vermeulen A, Verdonck L. Studies on the binding of testosterone to human plasma. Steroids. 1968;11:609-635.
9. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53:58-68.
10. Toorians AW, Kelleher S, Gooren LJ, et al. Estimating the contribution of the prostate to blood dihydrotestosterone. J Clin Endocrinol Metab. 2003;88:5207-5211.
11. Resko JA, Eik-nes KB. Diurnal testosterone levels in peripheral plasma of human male subjects. J Clin Endocrinol Metab. 1966;26:573-576.
12. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87:589-598.
13. Gray A, Feldman HA, McKinlay JB, et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016 -1025.
14. Vermeulen A, Kaufman JM, Goemaere S, et al. Estradiol in elderly men. Aging Male. 2002;5:98-102.
15. Vermeulen A. Sex hormones, body composition and aging. Aging Male. 2003;2:8-16.
16. Neaves WB, Johnson L, Porter JC, et al. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J Clin Endocrinol Metab. 1984;59:756-763.
17. Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab. 1995;80:3546-3552.
18. Veldhuis JD, Urban RJ, Dufau ML. Evidence that androgen negative feedback regulates hypothalamic gonadotropin-releasing hormone impulse strength and the burst-like secretion of biologically active luteinizing hormone in men. J Clin Endocrinol Metab. 1992;74:1227-1235.
19. Morley JE, Kaiser FE, Sih R, et al. Testosterone and frailty. Clin Geriatr Med. 1997;13:685-695.
20. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85:4500-4510.
21. Spratt DI, O'Dea LS, Schoenfeld D, et al. Neuroendocrine-gonadal axis in men: frequent sampling of LH, FSH, and testosterone. Am J Physiol. 1988;254(5 pt 1):E658-666.
22. Wang C, Catlin DH, Demers LM, et al. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2004;89:534-543.
23. Matsumoto AM, Bremner WJ. Serum testosterone assays: accuracy matters. J Clin Endocrinol Metab. 2004;89:520 -524.
24. Miller KK, Rosner W, Lee H, et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab. 2004;89:525-533.
25. Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56:M266-272.
26. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc. 2003;51:101-115; discussion 115.
27. Bhasin S, Bagatell CJ, Bremner WJ, et al. Issues in testosterone replacement in older men. J Clin Endocrinol Metab. 1998;83:3435-3448.
28. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl. 2006;27:135-137.
29. Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab. 1990;71:963-969.
30. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26: 833-876.
31. Kenny AM, McGee D, Joseph C, et al. Lack of association between androgen receptor polymorphisms and bone mineral density or physical function in older men. Endocr Res. 2005;31:285-293.
32. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab. 2004;89: 3813-3817.
33. Impallomeni M, Kaufman BM, Palmer AJ. Do acute diseases transiently impair anterior pituitary function in patients over the age of 75? a longitudinal study of the TRH test and basal gonadotrophin levels. Postgrad Med J. 1994;70:86-91.
34. Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab. 1996;81:1821-1826.
35. Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham Study. Ann Intern Med. 2000;133:951-963.
36. Barrett-Connor E, Mueller JE, von Muhlen DG, et al. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2000; 85:219-223.
37. Szulc P, Munoz F, Claustrat B, et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab. 2001;86:192-199.
38. Kenny AM, Prestwood KM, Marcello KM, et al. Determinants of bone density in healthy older men with low testosterone levels. J Gerontol A Biol Sci Med Sci. 2000;55:M492-497.
39. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:1966-1972.
40. Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81:4358-4365.
41. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89:503-510.
42. Crawford BA, Liu PY, Kean MT, et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab. 2003;88: 3167-3176.
43. Tracz MJ, Sideras K, Bolona ER, et al. Testosterone use in men and its effects on bone health: a systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006;91: 2011-2016.
44. Seidell JC, Bjorntorp P, Sjostrom L, et al. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 1990;39:897-901.
45. Tchernof A, Despres JP, Belanger A, et al. Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism. 1995;44:513-519.
46. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol. 1992;2:675-682.
47. Abassi A. Low circulating levels of insulin-like growth factors and testosterone in chronically institutionalized elderly men. J Am Geriatr Soc. 1993;41:975-982.
48. Baumgartner RN, Waters DL, Gallagher D, et al. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999;107: 123-136.
49. van den Beld AW, de Jong FH, Grobbee DE, et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000;85:3276-3282.
50. Roy TA, Blackman MR, Harman SM, et al. Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am J Physiol Endocrinol Metab. 2002;283:E284-294.
51. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:2647-2653.
52. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90:1502-1510.
53. Schiavi RC, Schreiner-Engel P, White D, et al. Pituitary-gonadal function during sleep in men with hypoactive sexual desire and in normal controls. Psychosom Med. 1988;50:304-318.
54. Tsitouras PD, Martin CE, Harman SM. Relationship of serum testosterone to sexual activity in healthy elderly men. J Gerontol. 1982;37:288-293.
55. Brill KT, Weltman AL, Gentili A, et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab. 2002;87:5649-5657.
56. Nankin HR, Lin T, Osterman J. Chronic testosterone cypionate therapy in men with secondary impotence. Fertil Steril. 1986;46:300-307.
57. Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88: 2673-2681.
58. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085-2098.
59. Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005;63:381-394.
60. Aversa A, Isidori AM, Spera G, et al. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf). 2003;58:632-638.
61. Shabsigh R, Kaufman JM, Steidle C, et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172:658-663.
62. Kwan M, Greenleaf WJ, Mann J, et al. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab. 1983;57:557-562.
63. Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis. 1996;125:1-13.
64. van den Beld AW, Bots ML, Janssen JA, et al. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003;157: 25-31.
65. Hak AE, Witteman JC, de Jong FH, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study. J Clin Endocrinol Metab. 2002;87:3632-3639.
66. Snyder PJ, Peachey H, Berlin JA, et al. Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am J Med. 2001;111:255-260.
67. English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102:1906-1911.
68. Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2002; 57:M460-465.
69. Liu PY, Wishart SM, Celermajer DS, et al. Do reproductive hormones modify insulin sensitivity and metabolism in older men? a randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol. 2003;148:55-66.
70. Ly LP, Jimenez M, Zhuang TN, et al. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab. 2001;86:4078-4088.
71. Ng MK, Liu PY, Williams AJ, et al. Prospective study of effect of androgens on serum inflammatory markers in men. Arterioscler Thromb Vasc Biol. 2002;22:1136-1141.
72. Simon D, Charles MA, Lahlou N, et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care. 2001;24:2149-2151.
73. Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899-906.
74. Reddy P, White CM, Dunn AB, et al. The effect of testosterone on health-related quality of life in elderly males: a pilot study. J Clin Pharm Ther. 2000;25:421-426.
75. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci. 1994;108:325-332.
76. Janowsky JS, Chavez B, Orwoll E. Sex steroids modify working memory. J Cogn Neurosci. 2000;12:407-414.
77. Kenny AM, Fabregas G, Song C, et al. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci. 2004;59:75-78.
78. Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82:1661-1667.
79. Kenny AM, Bellantonio S, Gruman CA, et al. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2002;57:M321-325.
80. Kelleher S, Conway AJ, Handelsman DJ. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clin Endocrinol (Oxf). 2001;55:531-536.
81. Huggins C, Stephens RC, Hodges CV. Studies on prostatic cancer: 2. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209.
82. Chen C, Weiss NS, Stanczyk FZ, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev. 2003;12: 1410-1416.
83. Hsing AW. Hormones and prostate cancer: what's next? Epidemiol Rev. 2001;23:42-58.
84. Gann PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118-1126.
85. Parsons JK, Carter HB, Platz EA, et al. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev. 2005;14:2257-2260.
86. Stattin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer. 2004;108:418-424.
87. Kleinman KP, McKinlay JB. Prostate cancer: how much do we know and how do we know it? Aging Male. 2000;3:115-123.
88. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482-492.
89. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451-1457.
90. Liverman CT, Blazer DG. Testosterone and aging, clinical research directions. Washington, DC: National Academies Press, 2004.
91. Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84: 3469-3478.
92. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000; 85:2839-2853.
93. Matsumoto AM, Sandblom RE, Schoene RB, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (Oxf). 1985;22:713-721.
94. Liu PY, Yee B, Wishart SM, et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab. 2003;88:3605-3613.
95. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995-2010.
96. Available at: http://www.cancer.org/docroot/PED/content/ PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp.